ILMN
ILLUMINA, INC.
Nasdaq: ILMN · San Diego, CA
$131.98-0.88 (-0.66%)Closed
Market Cap$20.19B
Cash$1.14Bmost recent
Runwayprofitable
P/E (TTM)24.2EPS $5.45
52-Wk Range$74.35 – $153.95
Avg Volume1.9M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$131.98+12.8%
Pipeline

Drug candidates sponsored by ILLUMINA · ClinicalTrials.gov

15 drugs · 17 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 318F-MFBG
Neuroblastoma+4 more
Recruiting
2026-07-30
3
Phase 118F-mFBG for intravenous administration
Cardiovascular Diseases
Completed
2025-03-07past
1
Phase 218F-metaFluorobenzylguanidine
Heart Failure+2 more
Not yet recruiting
2026-10-30
1
N/AUnnamed
Detection and Genotyping of Factor V and Factor II Point Mutations
Completed
2009-09past
1
N/AUnnamed
Post-natal Cytogenetics
Completed
2011-11past
1
N/AUnnamed
Infertility+1 more
Completed
2016-12-31past
1
N/AUnnamed
Preeclampsia
Completed
2017-11-20past
1
N/AUnnamed
Rare Diseases
Completed
2019-04-30past
1
N/AUnnamed
Pregnancy Related
Completed
2019-08-30past
1
N/AUnnamed
Pregnancy
Completed
2019-12-30past
1
N/AUnnamed
SARS-CoV-2
Completed
2021-02-28past
1
N/AUnnamed
SARS-CoV-2
Completed
2021-02-28past
1
N/AUnnamed
Genetic Disease
Active, not recruiting
2021-12-10past
1
N/AUnnamed
Neurologic Deficits+2 more
Completed
2024-01-31past
1
N/AUnnamed
Cardiovascular Diseases
Active, not recruiting
2024-12past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for ILMN. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.